pCDNA3.1(+)-CMV-bArrestin2-TEV
(Plasmid #107245)

• Purpose: Vector for preparation of stable cell lines expressing Barrestin2-TEV fusion protein in lieu of the HTLA cell line.
• Depositing Lab: Bryan Roth
• Publication: Kroeze et al Nat Struct Mol Biol. 2015 May;22(5):362-9. doi: 10.1038/nsmb.3014. Epub 2015 Apr 20.

Backbone

• Vector backbone: pCDNA3.1(+)
• Vector type: Mammalian Expression
• Selectable markers: Neomycin (select with G418)

Growth in Bacteria

• Bacterial Resistance(s): Ampicillin, 100 μg/mL
• Growth Temperature: 37°C
• Growth Strain(s): DH5alpha
• Copy number: High Copy

Gene/Insert

• Gene/Insert name: ARRB2
• Alt name: Beta Arrestin 2
• Species: Synthetic
• Insert Size (bp): 1962
• Promoter: CMV
• Tag / Fusion Protein:
  • TEV(NIA), tobacco etch virus NIA (C terminal on insert)

Cloning Information

• Cloning method: Gibson Cloning
• 5′ sequencing primer: CMV-F
• 3′ sequencing primer: BGH-R

Resource Information

• Supplemental Documents:
  • jge310_pcdna3-1-b-arrestin2-tev.gb
• A portion of this plasmid was derived from a plasmid made by: Custom synthesized
• Articles Citing this Plasmid:
  • 3 References

Terms and Licenses

• Academic/Nonprofit Terms:
  • UBMTA
• Industry Terms:
  • Not Available to Industry

Depositor Comments

These plasmids were generated as part of the Illuminating the Druggable Genome (IDG) program sponsored by the NIH Common Fund. The goal of this program is to identify, gather, and distribute information and resources for proteins that currently are not well-studied yet belong to commonly drug-targeted protein families: protein kinases, non-olfactory G-protein coupled receptors (GPCRs), and ion channels. The IDG program is designed to develop fundamental research tools for understudied proteins, elucidate their function, and disseminate the IDG-related resources and data to the greater scientific community.